Century Therapeutics (IPSC) Long-Term Investments (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Long-Term Investments of $82.2 million for Q1 2026, up 296.7% year-over-year from $20.7 million in Q1 2025, and up 2954.61% quarter-over-quarter from $2.7 million in Q2 2025.
Century Therapeutics (IPSC) Long-Term Investments (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Long-Term Investments for 7 consecutive years, with $82.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments rose 296.7% year-over-year to $82.2 million; the TTM figure through Mar 2026 stood at $82.2 million (up 296.7% YoY), while the FY2024 annual figure was $30.8 million, down 65.41% from the prior year.
- Long-Term Investments improved to $82.2 million in Q1 2026 per IPSC's latest filing, from $2.7 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $144.6 million in Q2 2023 and bottomed at $2.7 million in Q2 2025.
- Historically, Long-Term Investments has averaged $66.2 million across 5 years, with a median of $57.9 million in 2024.
- Annual changes were most pronounced in 2025 — Long-Term Investments sank 96.33% — and 2026, when it jumped 296.7%.
- Century Therapeutics' Long-Term Investments stood at $51.9 million in 2022, then soared by 71.82% to $89.1 million in 2023, then tumbled by 65.41% to $30.8 million in 2024, then tumbled by 91.27% to $2.7 million in 2025, then jumped by 2954.61% to $82.2 million in 2026.
- Business Quant data shows IPSC's Long-Term Investments at $82.2 million in Q1 2026, $2.7 million in Q2 2025, and $20.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | 77.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.48 Mn |
| Mar 31, 2026 | 82.17 Mn |
| Jun 30, 2025 | 2.69 Mn |
| Mar 31, 2025 | 20.71 Mn |
| Dec 31, 2024 | 30.82 Mn |
| Sep 30, 2024 | 46.57 Mn |
| Jun 30, 2024 | 73.23 Mn |
| Mar 31, 2024 | 57.85 Mn |
| Dec 31, 2023 | 89.10 Mn |
| Sep 30, 2023 | 114.76 Mn |
| Jun 30, 2023 | 144.58 Mn |
| Mar 31, 2023 | 83.32 Mn |
| Dec 31, 2022 | 51.85 Mn |
| Sep 30, 2022 | 39.43 Mn |
| Jun 30, 2022 | 50.61 Mn |
| Mar 31, 2022 | 105.36 Mn |
| Dec 31, 2021 | 135.91 Mn |
| Sep 30, 2021 | 105.19 Mn |
| Jun 30, 2021 | 42.47 Mn |
| Dec 31, 2020 | 1.05 Mn |